Gain Therapeutics Inc (GANX) Institutional Buying & Selling Tracker (Q2 2026)

GANX ranks #6175 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

50 institutions disclose a position in GANX, but none treat it as a major bet — even Potomac Capital Management, Inc., its most concentrated holder, allocates just 1.3% of its own portfolio to it.

GANX is down 6.4% today, but institutions show net buying of $1.1M this quarter — a divergence between today's price move and the underlying institutional flow.

GANX reported a net loss of $20.1M over the trailing twelve months.

• Not yet profitable — net loss of $20.1M over the trailing twelve months
• Revenue declined 58.4% year over year
• Net income declined year over year, from -$18.6M to -$20.1M
• Operating cash flow was negative, using $18.5M in cash
• Current ratio of 6.63x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.23x equity — within a conventional range